Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 1,738 trials

Colorectal Liver Metastases: IP-001 Immuno-Adjuvant Study

We are exploring a new treatment to see if it improves outcomes for patients with colorectal liver metastases after microwave ablation or electroporation. The study will help us understand the best dose and immune response.

Colorectal Liver Metastases>2 yearsSafety phase (I)Efficacy phase (II)GastroenterologyHepatologyInternal MedicineOncology

Carotid Stenosis: Ficolin-2 and Inflammation Study

We are investigating how levels of ficolin-2 relate to inflammation in the carotid arteries and brain in patients who have had a stroke or transient ischemic attack. This research may help us understand the underlying causes of these conditions better.

Stroke or Transient Ischemic Attack (TIA)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNeurology

Advanced Non-Small Cell Lung Cancer: THIO with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining THIO and cemiplimab for people with advanced non-small cell lung cancer. This trial aims to find out if this combination works better than THIO alone for patients who have already been treated.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Hepatocellular Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a combination of two medications for people with advanced liver cancer who have not had prior treatment. The goal is to find the best dose and assess safety and effectiveness.

Metastatic Liver Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Cell Therapy for Acute Kidney Injury After Heart Surgery

We are studying whether modified autologous leukocyte cells can help patients recover kidney function after developing acute kidney injury following cardiac surgery. The trial will also assess the safety of this new treatment.

Acute Kidney Injury6-12 monthsEfficacy phase (II)Investigational MedicinesCardiologyNephrology

Colorectal Liver Metastases: SGM-101 and Indocyanine Green Imaging

We are studying the use of two imaging agents during surgery for colorectal liver metastases to see if they help surgeons remove cancerous tissue more effectively. This trial aims to improve surgical accuracy and patient outcomes.

Liver Metastases1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Triple-Negative Breast Cancer: Pembrolizumab and Chemotherapy Study

We are investigating whether adding pembrolizumab to chemotherapy improves outcomes for patients with early-stage triple-negative breast cancer based on their tumor-infiltrating lymphocyte levels. This study also looks at the safety and quality of life for participants.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)Standard MedicinesOncology

Severe Brain Injury: Apomorphine Treatment Study

We are investigating whether apomorphine can help patients with disorders of consciousness. The study also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness≤3 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteNeurology

Advanced Tumors: TILs Treatment Study

We are studying a new therapy using tumor-infiltrating lymphocytes for patients with advanced tumors that have specific genetic changes. The goal is to see if this treatment can improve survival and tumor response.

Malignant Solid TumorEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Chronic Lymphocytic Leukemia: Zanubrutinib and Obinutuzumab Study

We are studying a combination of zanubrutinib and obinutuzumab for patients with untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The trial aims to see if this treatment helps achieve better remission rates compared to different schedules of drug administration.

Chronic Lymphocytic Leukemia (CLL)3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Richter Transformation: Testing New Combination Therapy

We are studying a combination of three medications for patients with Richter transformation of chronic lymphocytic leukemia. The goal is to evaluate how well this treatment works and its safety.

Chronic Lymphocytic Leukaemia Variants>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Cholestatic Pruritus: Volixibat Study

We are testing a new drug, volixibat, for patients with itching caused by primary biliary cholangitis. The study aims to see if it can reduce itching and improve quality of life compared to a placebo.

Primary Biliary Cholangitis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInternal Medicine

Small Cell Lung Cancer: Etoposide-Free Chemotherapy with Durvalumab

We are studying a new treatment combining chemotherapy and durvalumab for patients with extensive stage small cell lung cancer. The trial aims to see how well this treatment works and how it affects patients' quality of life.

Extensive Stage Small Cell Lung Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Anti-NMDA Receptor Encephalitis: Inebilizumab Study

We are testing a new treatment called inebilizumab for people with anti-NMDA receptor encephalitis. The study aims to see if it helps improve disability compared to a placebo.

Anti-NMDA Receptor Encephalitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia

We are studying a new treatment for children with relapsed or refractory Acute Lymphoblastic Leukemia to see how well it works and how safe it is. This trial includes both single-agent and combination therapy approaches.

Recurrent Pediatric Acute Lymphoblastic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Prostate Cancer: Estradiol and Exercise Study

We are exploring whether transdermal estradiol and resistance training can help reduce side effects like sexual dysfunction in men undergoing androgen deprivation therapy for prostate cancer. The study also looks at safety and quality of life improvements.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyUrology

HER2-Expressing Tumors: Trastuzumab Deruxtecan Study

We are studying the safety and effectiveness of Trastuzumab Deruxtecan in patients with advanced HER2-expressing tumors. This research aims to provide insights into new treatment possibilities for these patients.

HER2 Expressing Tumors6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Insomnia in Psychiatric Patients: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep and overall well-being in patients with psychiatric disorders and chronic insomnia. This trial compares these treatments to a placebo to find the most effective option.

Psychiatric Disorders and Insomnia>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPsychiatry

Cushing’s Disease: Lu AG13909 Treatment Study

We are investigating a new medication, Lu AG13909, for adults with Cushing’s disease to see how it affects cortisol levels and its safety. This trial aims to improve understanding of this rare condition and its treatment options.

Cushing's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine